Baidu
map

JACC:吃的太咸,长期死亡率增加

2016-10-05 MedSci MedSci原创

较低的钠摄入量和总死亡率之间的关系仍存在争议。来自美国的研究人员开展了一项研究,该研究的目的是评估钠摄入量(通过尿钠排泄中的钠含量检测)和长期死亡率之间的关系。研究人员开展了两项试验,第一阶段(1987至1990年),超过18个月,第二阶段(1990至1995年),36个月以上,这些试验均在TOHP试验(高血压干预试验)中进行,该试验实施了减少钠摄入量的措施。这些研究包括在试验期间的多个24小时的

较低的钠摄入量和总死亡率之间的关系仍存在争议。来自美国的研究人员开展了一项研究,该研究的目的是评估钠摄入量(通过尿钠排泄中的钠含量检测)和长期死亡率之间的关系。

研究人员开展了两项试验,第一阶段(1987至1990年),超过18个月,第二阶段(1990至1995年),36个月以上,这些试验均在TOHP试验(高血压干预试验)中进行,该试验实施了减少钠摄入量的措施。这些研究包括在试验期间的多个24小时的尿液样本,这些尿液样本来自于30至54岁的高血压前期人群。研究人员使用国家死亡指数确定了试验后死亡情况(平均超过24年)。研究人员对死亡率和随机干预措施以及与平均钠摄入量之间的关联进行了评估。

744名I期试验参与者和2382名II期试验参与者被随机分到减少钠摄入量组或对照组,该研究过程中共有251例死亡,这表明积极干预可降低15%的风险(风险比[HR]:0.85; 95%可信区间(CI):0.66〜1.09; P=0.19)。在未分配到积极干预的2974名参与者中,共有272人死亡。平均钠摄入量与死亡率之间有直接的线性关联,对于钠摄入量<2300,2300〜<3600,3,600〜<4,800,和≥4800mg/24小时,HR分别为0.75,0.95和1.00(参考)和1.07(趋势P=0.30);当钠摄入量为1000mg/24小时,HR为1.12(95%CI:1.00〜1.26; P =0.05)。没有J形或非线性关联的证据。钠/钾比每增加1个单位,HR则为1.13(95%CI:1.01〜1.27; P=0.04)。

研究人员发钠含量摄入水平较高,增加了死亡率,并且二者之间有直接的联系,即使钠摄入量较低时,也会增加死亡的风险。这些结果与减少钠和钠/钾的摄入量对总死亡率在20年期间的益处是一致的。

原始出处:

Nancy R. Cook,Lawrence J. Appel,Paul K. Whelton,Sodium Intake and All-Cause Mortality Over 20 Years in the Trials of Hypertension Prevention,JACC,2016.10.5

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853582, encodeId=8a4c1853582a1, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Mar 11 15:01:00 CST 2017, time=2017-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145945, encodeId=022514594548, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:28:14 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145943, encodeId=58ce14594383, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:28:07 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325302, encodeId=1d9a13253020c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Oct 07 12:01:00 CST 2016, time=2016-10-07, status=1, ipAttribution=)]
    2017-03-11 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853582, encodeId=8a4c1853582a1, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Mar 11 15:01:00 CST 2017, time=2017-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145945, encodeId=022514594548, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:28:14 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145943, encodeId=58ce14594383, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:28:07 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325302, encodeId=1d9a13253020c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Oct 07 12:01:00 CST 2016, time=2016-10-07, status=1, ipAttribution=)]
    2016-10-11 知难而进

    继续关注!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1853582, encodeId=8a4c1853582a1, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Mar 11 15:01:00 CST 2017, time=2017-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145945, encodeId=022514594548, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:28:14 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145943, encodeId=58ce14594383, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:28:07 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325302, encodeId=1d9a13253020c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Oct 07 12:01:00 CST 2016, time=2016-10-07, status=1, ipAttribution=)]
    2016-10-11 知难而进

    谢谢分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1853582, encodeId=8a4c1853582a1, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Mar 11 15:01:00 CST 2017, time=2017-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145945, encodeId=022514594548, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:28:14 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145943, encodeId=58ce14594383, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:28:07 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325302, encodeId=1d9a13253020c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Oct 07 12:01:00 CST 2016, time=2016-10-07, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map